Drug Overview Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.
This mechanism stands in contrast to GnRH agonists that, over time, downregulate and desensitize GnRH receptors in the pituitary, leading to reduced secretion of LH and downstream testosterone. However, GnRH agonists are also accompanied by a biochemical surge in testosterone known as a flare that typically requires co-administration of antiandrogens to help prevent flare side effects such as spinal cord compression, bone pain, and urethral obstruction
Our reports have been used by over 10K customers, including:
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 18.104.22.168) - Pipeline Review, H2 2016
Global Markets Direct’s, ‘Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 22.214.171.124) - Pipeline Review, H2 2016’, provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or...
Boehringer Ingelheim GmbH - Product Pipeline Review - 2016
Global Markets Direct’s, ‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus. The report provides comprehensive information on the...
Sodium-Glucose Co-Transporter 2 Inhibitor
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.